Author

K. M. Wilson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Cancer Biology· 2 Animal Behavior & Cognition· 1 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:drug response / drug discovery· 7 Organism:human· 3 Research Focus:benchmarking· 2 Assay:bulk RNA-seq· 2 Assay:proteomics· 2 Approach:Bayesian inference· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

C. Klumpp-Thomas· 6 shared M. D. Hall· 5 shared M. Shen· 5 shared Z. Itkin· 5 shared A. Simeonov· 4 shared P. Shinn· 4 shared C. Z. Chen· 3 shared H. Guo· 3 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersBiochemistry

C. Klumpp-Thomas

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions

K. M. Flickinger, K. M. Wilson, N. J. Rossiter, A. L. Hunger, T. D. Lee, M. D. Hall, J. R. Cantor

This study uses conditional lethality profiling in human plasma-like medium to identify drug mechanisms and interactions with nutrients, revealing new therapeutic strategies.

bioRxiv · Jun 4, 2023Cancer Biology

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

J. H. Shrimp, J. Janiszewski, C. Z. Chen, M. Xu, K. M. Wilson, S. C. Kales, P. E. Sanderson, P. Shinn, Z. Itkin, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, W. Zheng, A. Simeonov, M. D. Hall

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

bioRxiv · Feb 4, 2022Biochemistry

mTOR Inhibition Overcomes RSK3-mediated Resistance to BET Inhibitors in Small Cell Lung Cancer

A. Kumari, L. Gesumaria, Y.-J. Liu, V. K. Hughitt, X. Zhang, M. Ceribelli, K. M. Wilson, C. Klumpp-Thomas, L. Chen, C. McKnight, Z. Itkin, C. Thomas, B. A. Mock, D. S. Schrump, H. Chen

This study identifies mTOR inhibition as a strategy to overcome RSK3-mediated resistance to BET inhibitors in small cell lung cancer, enhancing apoptosis and antitumor efficacy.

bioRxiv · Nov 8, 2021Cancer Biology

Specificity of California mouse pup vocalizations in response to olfactory cues

K. M. Wilson, V. Wagner, W. Saltzman

This study investigates how olfactory cues affect pup vocalizations in California mice, finding differences based on litter size, sex, and odor type.

bioRxiv · Oct 12, 2021 · PreprintAnimal Behavior & Cognition

Cross-platform Bayesian optimization system for autonomous biological assay development

S. Elder, C. Klumpp-Thomas, A. Yasgar, J. Travers, S. Frebert, K. M. Wilson, A. V. Zakharov, J. L. Dahlin, C. Kreisbeck, D. Sheberla, G. S. Sittampalam, A. G. Godfrey, A. Simeonov, S. Michael

This paper develops a cross-platform Bayesian optimization system to accelerate biological assay development, reducing costs and time compared to brute force methods.

bioRxiv · Jun 23, 2021Biochemistry

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

C. Z. Chen, P. Shinn, Z. Itkin, R. Eastman, R. Bostwick, L. Rasmussen, R. Huang, M. Shen, X. Hu, K. M. Wilson, B. Brooks, H. Guo, T. Zhao, C. Klumpp-Thomas, A. Simeonov, , W. Zheng

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

bioRxiv · Aug 18, 2020Microbiology

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay

Q. M. Hanson, K. M. Wilson, M. Shen, Z. Itkin, R. T. Eastman, P. Shinn, M. D. Hall

The paper develops an AlphaLISA assay to measure SARS-CoV-2 spike RBD-ACE2 binding and identifies 25 drug candidates that disrupt this interaction.

bioRxiv · Jun 16, 2020Biochemistry

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, , M. D. Hall

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

bioRxiv · Jun 4, 2020 · PreprintBiochemistry

Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening

O. W. Lee, S. M. Austin, M. R. Gamma, D. M. Cheff, T. D. Lee, K. M. Wilson, J. M. Johnson, J. C. Travers, J. C. Braisted, R. Guha, C. Klumpp-Thomas, M. Shen, M. D. Hall

The paper profiles cytotoxicity of over 100,000 compounds across normal and cancer cell lines to identify cytotoxic compounds and improve screening efficiency.

bioRxiv · Feb 5, 2019Cell Biology